Table 1.
Clinicopathological characteristics of the 74 patients with OSCC and their association with EMMPRIN and Ki-67 expressions.
| Factor | N (%) | EMMPRIN overexpression | Ki-67 high expression | ||
|---|---|---|---|---|---|
| N (%) | P value | N (%) | P value | ||
| All cases | 74 (100%) | 56 (75.7%) | 38 (51.4%) | ||
| Gender | |||||
| Female | 19 (25.7%) | 11 (63.2%) | 0.140 | 8 (42.1%) | 0.350 |
| Male | 55 (74.3%) | 44 (80%) | 30 (54.5%) | ||
| Age | |||||
| <62 years | 37 (50%) | 30 (81.1%) | 0.278 | 22 (59.5%) | 0.163 |
| ≥62 years | 37 (50%) | 26 (70.3%) | 16 (43.2%) | ||
| Location | |||||
| Labial mucosa | 7 (9.5%) | 6 (85.7%) | 0.430 | 1 (14.3%) | 0.396 |
| Floor of the mouth | 10 (13.5%) | 7 (70%) | 8 (80%) | ||
| Tongue | 24 (32.4%) | 15 (62.5%) | 13 (54.2%) | ||
| Buccal mucosa | 5 (6.8%) | 5 (100%) | 2 (40%) | ||
| Retromolar trigone | 11 (14.9%) | 8 (72.7%) | 5 (45.5%) | ||
| Hard palate | 9 (12.2%) | 8 (88.9%) | 3 (55.6%) | ||
| Gingiva | 8 (10.8%) | 7 (87.5%) | 4 (50%) | ||
| Tumor size | |||||
| T1 | 13 (17.6%) | 8 (61.5%) | 0.132 | 6 (46.2%) | 0.396 |
| T2 | 29 (39.2%) | 20 (69%) | 12 (41.4%) | ||
| T3 | 9 (12.2%) | 9 (100%) | 6 (66.7%) | ||
| T4 | 23 (31%) | 19 (82.6%) | 14 (60.9%) | ||
| N status | |||||
| N0 | 41 (55.4%) | 28 (68.3%) | 0.349 | 16 (39%) | 0.052 |
| N1 | 12 (16.2%) | 11 (91.7%) | 7 (58.3%) | ||
| N2 | 17 (23%) | 14 (82.4%) | 11 (64.7%) | ||
| N3 | 4 (5.4%) | 3 (75%) | 4 (100%) | ||
| Stage | |||||
| I | 12 (16.2%) | 8 (66.7%) | 0.064 | 6 (50%) | 0.080 |
| II | 23 (31.1%) | 14 (60.9%) | 7 (30.4%) | ||
| III | 10 (13.5%) | 10 (100%) | 7 (70%) | ||
| IV | 29 (39.2%) | 24 (82.8%) | 18 (62.1%) | ||
| Treatment modality | |||||
| SG | 28 (37.8%) | 20 (71.4%) | 0.633 | 12 (42.9%) | 0.522 |
| SG + RT | 23 (31.3%) | 17 (73.9%) | 13 (56.5%) | ||
| CT + SG or RCT | 23 (31.3%) | 19 (82.6%) | 13 (56.5%) | ||
| Tumor grade | |||||
| G1 | 42 (56.8%) | 26 (61.9%) | 0.002 | 16 (38.1%) | 0.009 |
| G2 + G3 | 32 (43.2%) | 30 (93.8%) | 22 (68.8%) | ||
| Margin status* | |||||
| Free of tumor | 33 (57.9%) | 23 (69.7%) | 0.423 | 14 (42.4%) | 0.236 |
| With tumor | 24 (42.1%) | 19 (79.2%) | 14 (58.3%) | ||
| Perineural permeation | |||||
| Absent | 66 (89.2%) | 50 (75.8%) | 0.962 | 33 (50%) | 0.504 |
| Present | 8 (10.8%) | 6 (75%) | 5 (62.5%) | ||
| Lymphatic invasion | |||||
| Absent | 58 (78.4%) | 46 (79.3%) | 0.165 | 30 (51.7%) | 0.903 |
| Present | 16 (21.6%) | 10 (62.5%) | 8 (50%) | ||
SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
*Not determined in the 17 cases.